Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
+ catalysts driving successful decisions in life sciences real-world research and value insights from ispor international JUNE 2016 real-world research and value introduction As the healthcare market evolves it’s more crucial than ever to be able to provide evidence of your product’s value. Kantar Health has a long-standing track record of generating evidence for our clients to maximize the value of products in all stages of the lifecycle. it’s more crucial than ever to provide evidence of your product’s value. We understand the importance of value story creation. With a unique combination of broad, global, scientific expertise, backed by operational infrastructure, we fully execute all fieldwork and analyze, publish and communicate all of the data we generate. In total, our team has produced more than 1,500 publications in well-known scientific journals and conferences, adding more than 100 publications in 2015 alone. We invite you to explore our most recent research and look forward to your thoughts. Our real-world evidence and market access team recently presented more than 20 presentations at the ISPOR 21st Annual International Meeting, including research utilizing mHealth. We invite you to explore our most recent research and look forward to your thoughts. VALUE IDENTIFICATION © 2016 Kantar Health www.kantarhealth.com VALUE QUANTIFICATION VALUE COMMUNICATION 2 real-world research and value contents CONTENTS featured research Predictors of Intentional and Unintentional Non-Adherence and Associated Health Utilities Among Women Receiving Oral Treatments for Breast Cancer. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 The Real-World Pain Experience of Adults with Rheumatoid Arthritis Using a Mobile Survey. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 The Incremental Effect of Over-the-Counter Medications on Work Productivity and Healthcare Resource Utilization Among Adults with Pain in the United States. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 recent publications Therapeutic focus Cancer. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 Dermatologic Conditions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 Healthcare Use and Policy Studies. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 Infectious Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 Metabolic Conditions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 Methods. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 Muscular-Skeletal Disorders. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 Neurological Conditions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 Sensory System Disorders. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 © 2016 Kantar Health www.kantarhealth.com 3 real-world research and value Predictors of Intentional and Unintentional Non-Adherence and Associated Health Utilities Among Women Receiving Oral Treatments for Breast Cancer amir goren, phd Director, Health Outcomes Research shaloo gupta, MS Manager, Health Outcomes Research lulu lee, phd Manager, Health Outcomes Research non-adherence was found to be associated with age, with younger patients being more likely to be non-adherent than older patients. © 2016 Kantar Health The breast cancer (BC) market is seeing an increase in survivorship. To maintain longterm survival and prevent recurrence, adjuvant endocrine therapy (ET) is essential. Despite the importance of this therapy, many patients are non-adherent. In order to address this we explored predictors of unintentional non-adherence (UNA), such as forgetting to take medication, and intentional non-adherence (INA), such as not filling medications or deliberately skipping doses, in women receiving oral BC treatments. Data from the 2010-2015 U.S. National Health and Wellness Survey (NHWS) were used to evaluate the demographics and lifestyle behaviors of BC patients receiving adjuvant or metastatic oral therapies, as well as their health outcomes and quality of life (QoL, using Short-Form-6D health utilities (SF-6D)). Using the Morisky Medication Adherence Scale (MMAS) equivalent items from MMAS-4 and MMAS-8, we calculated scores to evaluate INA and UNA. Of BC patients surveyed, 6.0% reported INA, 22.4% reported UNA, and 3.2% reported both INA and UNA. Our research shows that those reporting INA were more likely to be younger, have normal BMI and have an income of $25,000 or less per year. Those reporting UNA were more likely to report lower rates of exercise and higher rates of smoking, and be obese and of non-white ethnicity. Non-adherence was found to be associated with age, with younger patients being more likely to be non-adherent than older patients, both intentionally and unintentionally. We also found that patients who are non-adherent (both INA and UNA), have significantly lower health utility scores than those who are adherent. Understanding the factors that contribute to non-adherence in breast cancer, including obesity, smoking and living a sedentary lifestyle, helps identify opportunities for targeted interventions, potentially improving outcomes and survivorship for at-risk populations. To read more about the study, see our research presentation, which was presented at the ISPOR 21st Annual International Meeting. REFERENCES: 1. Morisky et al. Med Care. 1986;24:67-74. 2. Morisky et al. J Clin Hypertens. 2008;10(5):348-354. www.kantarhealth.com 4 real-world research and value The Real-World Pain Experience of Adults with Rheumatoid Arthritis Using a Mobile Survey dave pomerantz Senior Vice President brian mondry Global Head of Digital Innovation Our mobile survey app allowed us to evaluate the ebbs and flows of patients’ symptom experience. Rheumatoid arthritis (RA) is associated with disability, decreased quality of life (QoL) and high societal burden. The condition is highly symptomatic, with pain being one of the most commonly experienced symptoms. Despite the significant impact that RA poses to patients and society, few studies have been published on how the condition affects patients’ day-to-day lives. To explore this, we used a mobile survey application to evaluate patients’ experience living with chronic pain in a real-world setting. To understand how disease affects patients’ lives not only at the clinical but emotional, quality-of-life level, we utilized our mobile survey app to deploy daily surveys to patients with RA who participated in a seven-day pain diary study. The survey allowed us to collect quantitative data, such as comorbidities and treatment, as well as questions related to the McGill Pain Questionnaire to rate their daily experience relating to 15 pain dimensions and pain intensity levels. Patients were also able to upload pictures with descriptive captions to further convey how they lived with chronic pain. Our study found that the most commonly experienced comorbidities were insomnia, anxiety and depression. To evaluate how these comorbidities related to patients’ pain experience, each dimension of pain was correlated by comorbidity and the level of pain intensity. We found that patients who described pain as “stabbing” were likely to experience anxiety and depression. We also found that those who described pain as “punishing” were likely to experience pain of greater intensity. This longitudinal, mobile-centric study allowed us to evaluate changes in patients’ experience over time versus at only one point, and how the ebbs and flows of their symptom experience affected their day-to-day lives and functioning. Understanding which dimensions of pain are most strongly associated with pain experience and health outcomes provides the insight needed to help inform disease management. To read more about the study, see our research poster, which was presented at the ISPOR 21st Annual International Meeting. © 2016 Kantar Health www.kantarhealth.com 5 real-world research and value The incremental effect of over-the-counter medications on work productivity and healthcare resource utilization among adults with pain in the united states ian kudel, phd Manager, Health Outcomes Research 82% of patients using otc medications to treat their pain symptoms do so without consulting a healthcare provider. Analgesics are the most commonly used over-the-counter (OTC) medications. Eighty-two percent of patients using OTC medications to treat their pain symptoms do so without consulting a healthcare provider. Pain is a highly prevalent and symptomatic condition and is associated with significant work productivity loss. With increased OTC options available to treat consumers’ pain symptoms, we sought to evaluate how the widespread use of these medications affected work productivity and healthcare resource use (HCRU). Participants in the 2013 U.S. National Health and Wellness Survey (NHWS) who reported experiencing pain in the previous 12 months were categorized into four groups: those who took no medication (untreated), those who used just an OTC (OTC only), those who used just a prescription medication (Rx), and those who used a combination of OTC and prescription medication (OTC+Rx). Their responses were compared across two sets of measures: work productivity (Work Productivity and Activity Impairment questionnaire) and self-reported HCRU. The OTC-only group had significantly lower rates of presenteeism, overall work impairment and activity impairment compared with the untreated group. Additionally, the OTC+Rx group had lower activity impairment than those taking a a prescription only. Comparisons of HCRU found that the OTC-only group reported fewer hospitalizations than the untreated group and that the OTC-only group reported fewer provider visits, hospitalizations and ER visits than the OTC+Rx group. These results may be attributed to OTC analgesics helping reduce pain symptoms, thus improving work productivity and reducing HCRU among U.S. adults experiencing pain. This study was sponsored by Pfizer, Inc. To read more about the study, see our research poster, which was presented at the ISPOR 21st Annual International Meeting. REFERENCES: 1. US Food and Drug Administration. Prescription to over-the-counter (OTC) switch list. Available at: http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ ucm106378.htm. Accessed: April 12, 2016. 2. Consumer Healthcare Products Association. The value of OTC medicine to the United States. Available at: http://www.chpa.org/OTCValue.aspx. Accessed: April 12, 2016 3.Consumer Healthcare Products Association. Your health at hand: perceptions of over-thecounter medicine in the U.S. Available at: http://www.yourhealthathand.org/images/uploads/ CHPA_YHH_Survey_062011.pdf. Accessed: April 12, 2016. 4.Lerner D, Rogers WH, Chang H, et al. The health care and productivity costs of back and neck pain in a multi-employer sample of utility industry employees. J Occup Environ Med. 2015;57(1):32-43. 5. Consumer Healthcare Products Association. Understanding trust in OTC medicines: consumer and healthcare provider perspectives. Available at: http://www.yourhealthathand.org/images/ uploads/CHPA_OTC_Trust_Survey_White_Paper.pdf. Accessed: April 12, 2016. 6. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353-365. © 2016 Kantar Health www.kantarhealth.com 6 real-world research and value recent publications Cancer ++ Government Reimbursement Values Versus Real Chemotherapy Costs in the Brazilian Public Healthcare System: Another Barrier to Treatment Access? Lemmer T, Goes L, Piedade AD ++ Predictors of Intentional and Unintentional Non-Adherence and Associated Health Utilities Among Women Receiving Oral Treatments for Breast Cancer Goren A, Gupta S, Lee L, Kuang-Yi W, Geynisman D ++ Intra-Operative Anastomotic Leak Rates and Testing Methodology in Colon Resection Surgery Schiff A, Roy S, Ghosh SK, Fegelman E, Pignot M ++ Retrospective Chart Review Study to Evaluate the Cost of Care of Patients with Symptomatic Multiple Myeloma in France Gonzalez-McQuire S, Yong K, Leleu H, Flinois A, Gazzola C, Schoen P, Campioni M, DeCosta L, Fink L ++ Retrospective Chart Review Study to Evaluate Healthcare Resource Utilization in Patients with Symptomatic Multiple Myeloma in Italy Gonzalez-McQuire S, Yong K, Flinois A, Gazzola C, Schoen P, Mennini FS, Campioni M, DeCosta L, Fink L ++ Chart Review Study to Evaluate Healthcare Resource Utilization of Patients with Symptomatic Multiple Myeloma in the United Kingdom Gonzalez-McQuire S, Yong K, Flinois A, Gazzola C, Schoen P, Campioni M, DeCosta L, Fink L DERMATOLOGIC CONDITIONS ++ The Burden of Atopic Dermatitis in Adults: Results from the 2013 United States National Health and Wellness Survey (NHWS) Whiteley J, Emir B, Seitzman R, Makinson G Healthcare use and policy studies ++ The Incremental Effect of Over-the-Counter Medications on Work Productivity and Healthcare Resource Utilization Among Adults with Pain in the United States Lee LJ, Kudel I, Schepart AL, Kellstein D ++ Patient Safety: An Overview of the Hospital Accreditation Process in Brazil Bueno CC, Alves AF, Retamero A, Castro AP, Clark LH, Clark OA ++ Improving Patient Safety Through Communication: A Brazilian Perspective Bueno CC, Almeida PR, Clark LG, Clark OA ++ Caregiver Burden in the United States Workforce: Healthcare Resource Utilization and Quality of Life Reimers Iadeluca L, Hopps M, Raghunath R, McDonald M, Makinson G © 2016 Kantar Health www.kantarhealth.com 7 real-world research and value Infectious Disease ++ Economic Impact of Dengue on Tourism in Brazil Nishikawa AM, Clark OA, Genovez V, Pinho A, Durand L ++ Public Health and Economic Impact of a Quadrivalent Influenza Vaccine in Comparison to the Trivalent Influenza Vaccine in Brazil over the Period of 2010-2013 Bricks L, Lopez JG, Macabeo B, Piedade AD, Clark OA, Nishikawa AM, Bottoni A, Gonclaves T Metabolic Conditions ++ Cost Analysis of Insulin Degludec in Comparison with Insulin Glargine U100 in the Treatment of Type 1 Diabetes Mellitus in the Brazilian Private Healthcare System Piedade AD, Paladini L, Alves JS, Gonclaves Td, Griciunas F ++ Cost Analysis of Insulin Degludec in Comparison with Insulin Glargine U100 in the Treatment of Type 1 Diabetes Mellitus in the Brazilian Public Healthcare System Piedade AD, Paladini L, Alves JS, Gonclaves Td, Griciunas F ++ Prevalence and Health Outcomes Associated with Types of Diabetes Complications Goren A, Strader C Methods ++ Application of Item Response Theory in Validating the Patient Health Questionnaire (PHQ-9) in the American General Population Gupta S, Witt E ++ Determining Whether Three Methods of Scoring a Patient-Reported Outcome Instrument Differentially Impacts Associations with Various Predictors Kudel I Muscular-Skeletal Disorders ++ The Real-World Experience of Adults with Rheumatoid Arthritis Using a Mobile Survey Pomerantz D, Mondry B neurological Disorders ++ Examining the Association Between Epilepsy Seizure Frequency and Health Economics Outcomes among Caregivers Helmers SL, Gupta S, Knoth R ++ The Burden of Multiple Sclerosis in Japan Yamabe K, Witt EA Sensory System Disorders ++ Incremental Burden of Cardiovascular Comorbidity or Psoriatic Arthritis Among Individuals with Moderate to Severe Psoriasis Augustin M, Tian H, Gilloteau I, Mollon P, Vietri J © 2016 Kantar Health www.kantarhealth.com 8 real-world research and value real-world research and value Advancing Healthcare and Driving Better Patient Outcomes Kantar Health is a world-class evidence specialist with the most comprehensive databases across the globe. Whether your need originates from market access, medical affairs or health economics and outcomes research, we can help you with: ++ Value Strategies ++ Strategic Market Access ++ Pricing and Reimbursement ++ Health Economics and Outcomes Research (HEOR) ++ Patient-Reported Outcomes ++ Observational Studies and Registries ++ Phase IV Studies ++ Post-Authorization Safety and Efficacy Studies (PASS/PAES) ++ Risk Management and Pharmacoepidemiology ++ Systematic Literature Reviews ++ Real-World Evidence Proprietary Databases © 2016 Kantar Health www.kantarhealth.com 9 real-world research and value why kantar health Kantar Health is a leading global healthcare consulting firm and trusted advisor to many of the world’s leading pharmaceutical, biotech and medical device and diagnostic companies. It combines evidence-based research capabilities with deep scientific, therapeutic and clinical knowledge, commercial development know-how, and brand and marketing expertise to help clients evaluate opportunities, launch products and maintain brand and market leadership. Kantar Health deeply understands the influence of patients, payers and physicians, especially as they relate to the performance and payment of medicines and the delivery of healthcare services. Our advisory services, built on a solid foundation of market research and data, span three areas critical to bringing new medicines and pharmaceutical products to market – commercial development, clinical strategies and marketing effectiveness. Kantar Health operates in more than 40 countries and employs more than 600 healthcare industry specialists and practitioners, including a high number of medical doctors, epidemiologists, PhDs, PharmDs and pharmacists, and biologists, biochemists and biophysicists. We work across the product lifecycle, from preclinical development to launch, and are experts at bringing multiple stakeholders together to advance the commercialization of pharmaceutical products. Our team acts as catalysts to successful decision making in the life sciences industry, helping our clients prioritize their product development and portfolio activities, differentiate their brands and drive product success post-launch. Kantar Health is part of Kantar, the data investment management division of WPP. If you would like us to act as catalysts for you, contact us at www.kantarhealth.com/ contactus. © 2016 Kantar Health www.kantarhealth.com 10